Results
| PMID | 14644829 |
| Gene Name | IGFBP3 |
| Condition | Endometriosis |
| Association |
Associated |
| Sex | Female |
| Associated genes | uPA, IGFBP-3 |
| Other associated phenotypes |
Endometriosis |
|
Ann N Y Acad Sci. 2003 Nov;997:223-8. Lembessis, Peter| Milingos, Spyros| Michalas, Stelios| Milingos, Dimitris| Creatsas, George| Sourla, Antigone| Koutsilieris, Michael Department of Experimental Physiology, University of Athens Medical School, 75 Micras Athens, Goudi-Athens 115 27, Greece. The peritoneal fluid of women with endometriosis contains an increased insulin-like growth factor 1 (IGF-1) bioavailability, which is produced by limited hydrolysis of urokinase-type plasminogen activator (uPA) on IGF-binding protein 3 (IGFBP-3). Recently, IGF-1 was shown to inhibit apoptosis of endometrial-like cells in vitro, suggesting that a microenvironment of increased IGF-1 bioavailability can optimize the survival of endometrial cells grown ectopically. Here the expression of mRNA of IGFBP-3 and uPA in tissue biopsies from eutopic endometrium and endometriotic lesions obtained at laparoscopy from women with endometriosis have been analyzed, and it is documented that both IGFBP-3 and uPA mRNA expression are increased from 3- to 10-fold in endometriotic lesions versus eutopic endometrium. Consequently, the necessary components (uPA and IGFBP-3 expression) of endocrine/autocrine/paracrine enhancement of local IGF bioavailability mediated by uPA hydrolysis of the IGFBP-3 were present in endometriotic lesions. These data possibly explain the origin of the increased content of uPA activity, IGF-1 bioavailability, and NH(2)-truncated forms of IGFBP-3 in the peritoneal fluid of women with endometriosis. Mesh Terms: Ascitic Fluid| Biopsy, Needle| Case-Control Studies| Culture Techniques| Endometriosis/genetics/*pathology| Female| Gene Expression Regulation| Genetic Markers| *Genetic Predisposition to Disease| Humans| Insulin-Like Growth Factor Binding Prote |
|